Collexis Holdings, Inc. Acquires SyynX Solutions GmbH, Expands Application Portfolio

SyynX Solutions GmbHCollexis Holdings, Inc. (OTCBB: CLXS) has acquired its long-time development partner, SyynX Solutions, a privately-held software company based in Cologne, Germany. SyynX Solutions will remain as a subsidiary of Collexis Holdings – with the amendment "a Collexis company", and will take care of existing customers and drive Collexis' business in Europe. The SyynX management team will be part of the Collexis Holdings management team.

The joint history of both companies:
SyynX and Collexis were founded at the same time in 1999 as offspring of an EU funded research project. SyynX started then to develop parts of the fingerprint technology for Collexis. In less than ten years Collexis has become the market leader of knowledge applications especially for the scientific context. In 2005 Collexis moved its global headquarters to Columbia, South Carolina and introduced the SyynX applications to the American market. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). The applications developed by SyynX are based on the patented Collexis fingerprint technology, i.e. the Knowledge or Protein Dashboard, the search platform Mediator and the Social Networking platform for the Life Sciences with more than 1M of pre-populated expert profiles. The later was recently jointly developed with Collexis and will be launched at the beginning of 2008.

"After working together with the Collexis team for several years, the SyynX team is more than excited about bringing the two companies together," says Christian Herzog, MD, CEO of SyynX Solutions. "The Collexis Fingerprint core technology, combined with the applications built by SyynX, will provide a great advantage to existing customers, as well as future ones."

Bill Kirkland, CEO of Collexis. "The SyynX software component is an ideal strategic complement to our existing capabilities as the market leader in high-definition search and discovery solutions. Our comprehensive offerings address a growing market trend, as scientists are increasingly recognizing the essential role that informatics, database and workflow solutions play in more effectively managing research programs and driving higher productivity. We believe that the acquisition of SyynX will position Collexis as a global leader in providing these solutions and our value proposition to clients will be stronger as a result."

Related news article:

About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of High Definition Search and Discovery software since 1999, is headquartered in Columbia, South Carolina (USA) with two subsidiaries; Collexis Inc. in Columbia, South Carolina, USA and Collexis, B.V. in Geldermalsen, The Netherlands. Collexis proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, websites, e-mails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis shares of common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, please visit www.collexis.com.

About SyynX Solutions GmbH
SyynX Solutions GmbH is a German software company which focuses on text mining based applications for the areas of life science and health care. Collexis and SyynX are already co-operating closely since almost ten years on the technical and commercial level. The SyynX applications based on the Collexis fingerprint technology are used by customers like universities, pharmaceutical and biotech companies around the world. The text mining applications like the SyynX Knowledge Dashboard helps the user to analyze large text corpora without applying standard search approaches and provides him automatically with expert profiles, trends and knowledge discovery routines. For more information please visit www.syynx.de.

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 2...